mRNA-4157/V940in combination with Keytruda receives PRIME scheme designation from EMA
Designation based on positive data from Phase 2b KEYNOTE-942/mRNA-4157-P201 trial and unmet need for additional therapeutic options for certain types of melanoma
Designation based on positive data from Phase 2b KEYNOTE-942/mRNA-4157-P201 trial and unmet need for additional therapeutic options for certain types of melanoma
Designation based on positive data from Phase 2b KEYNOTE-942/mRNA-4157-P201 trial
Subscribe To Our Newsletter & Stay Updated